US Patent No. 6,180,346 B1 Issues to Xanthon

Apr 23, 2001, 01:00 ET from Xanthon Inc.

    RESEARCH TRIANGLE PARK, N.C., April 23 /PRNewswire Interactive News
 Release/ -- Xanthon Inc. announced today that the United States Patent and
 Trademark Office has issued Patent No. 6,180,346 B1 entitled,
 Electropolymerizable Film and Method of Making and Use Thereof.  This patent
 is a continuation-in-part of United States Patent No. 5,871,918 entitled
 Electrochemical Detection of Nucleic Acid Hybridization.  Both patents are
 exclusively licensed by Xanthon from the University of North Carolina at
 Chapel Hill on a worldwide basis.
     Dr. Holden Thorp, Professor of Chemistry at the University of North
 Carolina at Chapel Hill and Co-founder of Xanthon, explained, "This patent
 describes, among other things, an electrode and a unique method for
 electropolymerizing a film onto the conductive working surface and covalently
 attaching a DNA probe to the film.  This technology is particularly exciting
 as it provides Xanthon with a unique means of specifically attaching a probe
 to an individual binding site on an electrode without the use of a precision
 mechanical deposition instrument -- a discovery that could significantly
 improve the efficiency of multiplexed microarray manufacturing."
     Xanthon is in the final stages of optimization and validation of their
 first product, the XANTHON XPRESSION ANALYSIS SYSTEM(TM).  Research and
 development efforts are ongoing to increase the multiplex capability of the
 expression analysis platform and efficiency of manufacturing as well as to
 develop new products for SNP detection and protein analysis based upon the
 Xanthon technology.  Xanthon continues work to discover new technologies that
 broaden the range of products that the Company will offer to the drug
 discovery and biotechnology marketplaces.
     Xanthon is a bioinformation solutions company created to commercialize its
 patented electrochemical detection technology for the direct analysis of DNA,
 RNA, and proteins.  The Company's first products will be launched to
 pharmaceutical companies early next year for high throughput gene expression
 analysis applications for drug discovery.  Future Xanthon products will
 include the XANTHON SNP ANALYSIS SYSTEM(TM) and the XANTHON PROTEOMICS
 ANALYSIS SYSTEM(TM).
 
     Contact:
 
     Susan L. Taylor
     Director of Corporate Communications
     (919) 572-0707
     staylor@xanthon.com
 
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X15518231
 
 

SOURCE Xanthon Inc.
    RESEARCH TRIANGLE PARK, N.C., April 23 /PRNewswire Interactive News
 Release/ -- Xanthon Inc. announced today that the United States Patent and
 Trademark Office has issued Patent No. 6,180,346 B1 entitled,
 Electropolymerizable Film and Method of Making and Use Thereof.  This patent
 is a continuation-in-part of United States Patent No. 5,871,918 entitled
 Electrochemical Detection of Nucleic Acid Hybridization.  Both patents are
 exclusively licensed by Xanthon from the University of North Carolina at
 Chapel Hill on a worldwide basis.
     Dr. Holden Thorp, Professor of Chemistry at the University of North
 Carolina at Chapel Hill and Co-founder of Xanthon, explained, "This patent
 describes, among other things, an electrode and a unique method for
 electropolymerizing a film onto the conductive working surface and covalently
 attaching a DNA probe to the film.  This technology is particularly exciting
 as it provides Xanthon with a unique means of specifically attaching a probe
 to an individual binding site on an electrode without the use of a precision
 mechanical deposition instrument -- a discovery that could significantly
 improve the efficiency of multiplexed microarray manufacturing."
     Xanthon is in the final stages of optimization and validation of their
 first product, the XANTHON XPRESSION ANALYSIS SYSTEM(TM).  Research and
 development efforts are ongoing to increase the multiplex capability of the
 expression analysis platform and efficiency of manufacturing as well as to
 develop new products for SNP detection and protein analysis based upon the
 Xanthon technology.  Xanthon continues work to discover new technologies that
 broaden the range of products that the Company will offer to the drug
 discovery and biotechnology marketplaces.
     Xanthon is a bioinformation solutions company created to commercialize its
 patented electrochemical detection technology for the direct analysis of DNA,
 RNA, and proteins.  The Company's first products will be launched to
 pharmaceutical companies early next year for high throughput gene expression
 analysis applications for drug discovery.  Future Xanthon products will
 include the XANTHON SNP ANALYSIS SYSTEM(TM) and the XANTHON PROTEOMICS
 ANALYSIS SYSTEM(TM).
 
     Contact:
 
     Susan L. Taylor
     Director of Corporate Communications
     (919) 572-0707
     staylor@xanthon.com
 
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X15518231
 
 SOURCE  Xanthon Inc.